(Q21260279)

6 July 2017

title

Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia (English)

1 reference

6 July 2017

0 references

1

Haya Ascher-Svanum

Haya

Ascher-Svanum

1 reference

6 July 2017

Baojin Zhu

2

Baojin

Zhu

1 reference

6 July 2017

Douglas Faries

3

Douglas

Faries

1 reference

6 July 2017

Ron Landbloom

4

Ron

Landbloom

1 reference

6 July 2017

Marvin Swartz

5

Marvin

Swartz

1 reference

6 July 2017

Jeff Swanson

6

Jeff

Swanson

1 reference

6 July 2017

language of work or name

English

0 references

publication date

21 February 2006

1 reference

6 July 2017

1 reference

6 July 2017

volume

6

1 reference

6 July 2017

issue

1

0 references

page(s)

8

1 reference

Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs

6 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

Practice guideline for the treatment of patients with schizophrenia, second edition.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

A meta-analysis of the efficacy of second-generation antipsychotics

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

An economic review of compliance with medication therapy in the treatment of schizophrenia

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

Dropout rates in randomised antipsychotic drug trials

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

Using drug claims data to assess the relationship of medication adherence with hospitalization and costs

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

Episodes of mental health and substance abuse treatment under a managed behavioral health care carve-out.

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

Effect of mental health specialty care on antidepressant length of therapy

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

Compliance with medication regimens for mental and physical disorders

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

Estimation of antipsychotic effects on hospitalization risk in a naturalistic study with selection on unobservables

12 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

Discovering the neural basis of human social anxiety: a diagnostic and therapeutic imperative

27 September 2017

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-8

Atypical Antipsychotics in First Admission Schizophrenia: Medication Continuation and Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-8

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-8

Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-8

The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): an instrument to assess outcomes of schizophrenia care

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-8

Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-8

The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-8

Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-8

Less medication switching after initial start with atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-8

Predictors of Risk of Nonadherence in Outpatients With Schizophrenia and Other Psychotic Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-8

Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-8

Sex, GABA, and nicotine: the impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-8

Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-8

A sharper Bonferroni procedure for multiple tests of significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-244X-6-8

Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia

29 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1402287

Intermittent vs maintenance medication in schizophrenia. Two-year results

29 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16504026

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/1471-244X-6-8

1 reference

Dimensions Publication ID

6 July 2017

1 reference

9 September 2019

https://scigraph.springernature.com/pub.10.1186/1471-244x-6-8

OpenCitations bibliographic resource ID

4415419

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1 reference

6 July 2017

1 reference